Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Cummins Inc Q1 2026 Earnings Call - Power Generation and Truck Demand Drive Raised 2026 Outlook
Cummins Inc. delivered a solid Q1 2026, with revenues rising 3% to $8.4 billion, driven by surging power generation demand from data centers and improving North American truck volumes. The company rai...
- Q1 2026 revenues reached $8.4 billion, a 3% increase year-over-year, driven by power generation demand and improving truck volumes.
- North American heavy-duty truck industry production fell 23% in Q1, but Cummins raised its full-year 2026 forecast to 230,000-250,000 units, up from prior guidance of 220,000-240,000 units.
- Power generation revenues surged 23% in Q1, fueled by accelerating data center demand, particularly in China and Asia Pacific.
- +7 more takeaways
Protalix BioTherapeutics Q1 2026 Earnings Call - $25M Milestone Boosts Cash to $51M, Reaffirms 2026 Guidance
Protalix BioTherapeutics reported a solid first quarter for 2026, driven by a $25 million milestone payment from Chiesi following the European Commission's approval of an every-four-weeks dosing regim...
- Protalix received a $25 million milestone payment from Chiesi after the European Commission approved an every-four-weeks dosing regimen for Elfabrio, a key rare disease treatment.
- Cash and short-term bank deposits reached $51 million as of March 31, 2026, providing substantial financial flexibility with no outstanding debt or warrants.
- Full-year 2026 revenue guidance is reaffirmed at $78 million to $83 million, including the $25 million milestone, with Elfabrio product sales expected at $33 million to $35 million and Elelyso at $20 million to $23 million.
- +9 more takeaways
Innate Pharma
Innate Pharma is executing a disciplined, three-asset strategy with a clear focus on commercial validation and non-dilutive financing. Lacutamab, their anti-KIR3DL2 antibody for cutaneous T-cell lymph...
- FDA clearance secured for lacutamab’s TELLOMAK-3 phase III trial in CTCL, with initiation expected in H2 2026.
- Lacutamab partnership or royalty financing deal anticipated before Q3 2026 to fund phase III initiation.
- IPH4502, a Nectin-4 ADC, is nearing completion of dose-escalation with preliminary antitumor activity in urothelial cancer.
- +7 more takeaways
Atour Lifestyle Holdings Q1 2026 Earnings Call - Retail Revenue Surge Drives Full-Year Guidance Upgrade
Atour Lifestyle Holdings delivered a robust first quarter of 2026, with net revenue jumping 47.5% year-over-year to RMB 2.81 billion. The standout story was retail, which surged 54.4% to RMB 1.07 bill...
- Net revenue grew 47.5% year-over-year to RMB 2.81 billion, driven by hotel expansion and retail strength.
- Retail revenue surged 54.4% to RMB 1.07 billion, leading management to upgrade full-year retail guidance to 30-35% growth.
- RevPAR reached 102.4% of prior-year levels, with ADR and occupancy both up 2.1% year-over-year.
- +7 more takeaways
Tecnoglass Inc. Q1 2026 Earnings Call - Record Backlog and Tariff Resilience
Tecnoglass delivered a record first quarter with revenues climbing 12% to $249 million, driven by a 20.4% surge in multifamily and commercial sales. The company closed the quarter with a record $1.36 ...
- Record backlog of $1.36 billion, up 19.1% year-over-year, with a book-to-bill ratio of 1.3x extending a 21-quarter streak above 1.1x.
- Q1 revenues reached a first-quarter record of $249 million, a 12% year-over-year increase, driven by a 20.4% surge in multifamily and commercial segments.
- Single-family residential revenues were essentially flat year-over-year, though orders grew 3.4% year-over-year and 14.1% sequentially, signaling underlying demand resilience.
- +9 more takeaways
Blue Owl Technology Finance Corp Q1 2026 Earnings Call - Software Credit Stress Masks Durable Fundamentals
Blue Owl Technology Finance Corp reported Q1 2026 adjusted net investment income of $0.29 per share, with NAV declining to $16.49 due to mark-to-market pressure from widening software credit spreads. ...
- Adjusted net investment income came in at $0.29 per share, down from prior periods due to lower base rates, tighter spreads on newer originations, and a $0.08 per share hit from capital gains incentive fee reversals tied to equity mark-to-market losses.
- NAV declined to $16.49 per share from $17.33, primarily driven by spread widening across technology credit rather than fundamental credit deterioration.
- Non-accruals remain exceptionally low at 10 basis points of the portfolio, with no new non-accruals added during the quarter, underscoring the resilience of the underlying asset quality.
- +7 more takeaways
Magnera Q2 2026 Earnings Call - Storms and Geopolitical Headwinds Offset by Strong Cash Flow and Localized Sourcing
Magnera reported Q2 2026 adjusted EBITDA of $90 million, in line with expectations after accounting for weather-related disruptions from winter storms Fern and Hernando, which temporarily shut down 20...
- Adjusted EBITDA came in at $90 million, meeting expectations after adjusting for weather-related disruptions.
- Winter storms Fern and Hernando temporarily shut down 20 manufacturing sites, resulting in an estimated $5 million EBITDA hit.
- Free cash flow reached $73 million in the quarter, supporting a $36 million debt repayment.
- +12 more takeaways
Chicago Atlantic Real Estate Finance Inc. {Q1} {2026} Earnings Call - Cannabis Rescheduling Boosts Cash Flow, CECL Rises on Loan Downgrades
Chicago Atlantic Real Estate Finance delivered steady Q1 2026 results despite a volatile macro backdrop and the Fed pausing its rate-cut cycle. The catalyst was the DOJ’s April 23 decision to reschedu...
- DOJ reschedules medical marijuana to Schedule III, eliminating Section 280E tax burdens and improving borrower cash flows.
- Portfolio principal stands at $414 million across 25 companies, with a weighted average yield of 15.8%.
- CECL reserves increased by $3.8 million to $8.7 million, driven by Loan No. 36 downgraded to risk rating four.
- +7 more takeaways
Grifols Q1 2026 Earnings Call - Egypt Plasma Milestone Drives Structural Margin Expansion
Grifols delivered a resilient Q1 2026, with revenue up 3.3% at constant currency and Biopharma growth accelerating to 6.8%, led by double-digit momentum in immunoglobulins. The company is executing a ...
- Revenue reached EUR 1.7 billion, up 3.3% at constant currency, with Biopharma leading growth at 6.8%.
- Egypt plasma platform approved by EMA, targeting 1 million liters in 2026 and 3 million by 2029 to reduce U.S. dependency.
- Immunoglobulin franchise grew 15.3%, driven by Gamunex and the U.S. launch of Biotest’s Yimmugo.
- +7 more takeaways
Aemetis Q1 2026 Earnings Call - Financial Inflection Point Driven by LCFS Pathway Approvals and MVR Commissioning
Aemetis delivered a clear financial inflection point in Q1 2026, growing revenue 27% year-over-year to $54.6 million and flipping gross profit from a $5.1 million loss to a $2.8 million gain. The impr...
- Revenue grew 27% year-over-year to $54.6 million, with positive gross profit of $2.8 million versus a $5.1 million gross loss in Q1 2025.
- Operating loss improved 60% to $6.3 million, and net loss narrowed to $21.7 million from $24.5 million in the prior year period.
- Section 45Z production tax credits contributed $4 million in operating income, with $1.4 million from dairy RNG and $2.6 million from California ethanol.
- +10 more takeaways